An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines

AIDS Research and Human Retroviruses

Volumn 15, Issue 11, 1999, Pages 1021-1034

  Carruth, Lucy M ^a   Greten, Tim F ^a   Murray, Cristin E ^a   Castro, Monica G ^a   Crone, Sylvia N ^a   Pavlat, Wendy ^a   Schneck, Jonathan P ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS INFECTION;

AIDS VACCINES; ALGORITHMS; ANIMALS; ANTIGEN PRESENTATION; AVIPOXVIRUS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, VIRAL; FLOW CYTOMETRY; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV SERONEGATIVITY; HIV-1; HUMANS; MICE; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033587607     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310539     Document Type: Article

References (72)

1. Yap KL, Ada GL, and McKenzie IFC: Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature (London) 1978;273:238-239.
2. Lin YL and Askonas BA: Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed type hypersensitivity reactions. J Exp Med 1981;154:225-234.
3. Quinnan GV, Kirmani N, Rook AHM, Jackson I, Moreschi G, Santos GW, Saral R, and Burns WH: Cytotoxic T cells in cytomegalovirus infection HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 1982;307:7-13.
4. Lukacher AE, Braciale VL, and Braciale TJ: In vivo effector function and influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984;160:814-826.
5. Del Val M, Schlicht HJ, Volkmer H, Messerle M, Reddehase MJ, and Koszinowsk UH: Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 1991;65:3641-3646.
6. Riddell SR, Wantanabe KS, Goodrich JM, Li CR, Agha ME, and Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241.
7. Reusser P, Riddell SR, Meyers JD, and Greenberg PD: Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytometgalovirus infection and disease. Blood 1991;78: 1373-1380.
8. 8: Yasutomi Y, Reimann KA, Lord CI, Miller MD, and Letvin NL: Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol 1993;67: 1707-1711.
9. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, and Stott J: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med 1995;1:1167-1173.
10. Borrow P, Lewicki H, Hahn BH, Shaw GW, and Oldstone MB: Virus-specific CD8+ cytotoxic T lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
11. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
12. Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, and McMichael AJ: Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma viral RNA. Science 1998;279:2103-2106.
13. Musey L, Hughes J, Schacker T, Shea T, Corey L, and McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-1274.
14. Ferbas J, Kaplan AH, Hausner MA, Hultin LE, Matud JL, Zhiyuan L, Panicali DL, Nerng H, Ho R, Detels R, and Giorgi JV: Virus burden in long term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity. J Infect Dis 1995;172:329-339.
15. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Buchbinder S, and Walker BD: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. J Immunol 1996;156:2616-2623.
16. Harrer T, Harrer E, Kalams SA, Trocha A, Johnson RP, Elbeik T, Feinberg MB, Cao Y, Ho DD, Buchbinder S, and Walker BD: Strong cytotoxic T cells and weak neutralizing antibody in long-term nonprogressing HIV-1 infection. AIDS Res Hum Retroviruses 1996;12:585-592.
17. Rinaldo C, Huang X-L, Fan Z, Ding M, Bletz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M, and Gupta P: High levels of anti human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69:5838-5842.
18. Carmichael A, Jin X, Sissons P, and Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 nfection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993;177:249-256.
19. Klein MR and van Baalen CA: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long term asymptomatics. J Exp Med 1995;181:1356-1372.
20. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak M, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, and Rowland-Jones S: Late escape from immunodominant cytotoxic T lymphocyte response associated with progression to AIDs. J Exp Med 1997;3:212-217.
21. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MBA, and Shaw GM: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. J Exp Med 1997;3:205-211.
22. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, Landay AL, and Shearer GM: Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-1 contaminated body fluids. J Clin Invest 1995;96:867-876.
23. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, and Whittle H: HIV-specific cytotoxic T cells in HIV-exposed but uninfected Gambian women. Nature Med 1995;1:59-64.
24. Langelade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, and Oskenheldler E: Human immunodeficiency virus type (HIV) Nef-specific cytotoxic T lymphocytes in noninfected heterosexual contacts of HIV-infected patients. J Clin Invest 1993;93:1292-1297.
25. Stanhope PE, Liu AY, Pavlat W, Pitha PM, Clements ML, and Siliciano RF: An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J Immunol 1993;150:4672-4686.
26. Stanhope PE, Clements ML, and Siliciano RF: Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993;168:92-100.
27. + human CTL induced by candidate AIDS vaccines. J Immunol 1994;153:2787-2799.
28. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, and Fast PE: Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996;125:270-279.
29. Dolin R, Graham BS, Greenberg B, Tacket CO, Belshe RB, Midthun K, Clements ML, Gorse GJ, Horgan BW, Atmar RL, Karzon DT, Bonnez W, Fernie BF, Montefiori DC, Stablein DM, Smith GM, Koff WC, and the NIAID AIDS Vaccine Clinical Trials Network: The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991;114:119-127.
30. Orentas RJ, Hildreth JE, Obah E, Polydefkis M, Smith GE, Clements ML, and Siliciano RF: Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-1237.
31. Hammond SA, Bollinger RC, Stanhope PE, Quinn TC, Schwartz D, Clements ML, and Siliciano RF: Comparative clonal anlaysis of human immunodeficiency virus type 1 (HFV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-1542.
32. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-1886.
33. McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, and Greenberg PD: Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: Analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994;169: 41-47.
34. Tartaglia J, Jarrett O, Neil JC, Desmettre P, and Paoletti E: Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993;4: 2370-2375.
35. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, and Plotkin S: Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine 1996;14:428-434.
36. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, and Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-1432.
37. Pardo MC, Bauman JE, and Mackowiak M: Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res 1997;58:833-837.
38. Stephensen CB, Welter J, Thaker SR, Taylor J, Tartaglia J, and Paoletti E: Canine distemper virus (CDV) infection of ferrets as a model for testing morbillivirus vaccine strategies: NYVAC-and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol 1997;71:1506-1513.
39. Konishi E, Kurane I, Mason PW, Shope RE, and Ennis FA: Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice. Virology 1997;227:353-360.
40. Gönczöl E, Berensci K, Pincus S, Endresz V, Méric C, Paoletti E, and Plotkin S: Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1997;13:1080-1085.
41. Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, and Siliciano RF: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating host-range-restricted canarypox vector (ALVAC) carrying the HIV-1(MN) env gene. J Infect Dis 1995;71:1623-1627.
42. Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, and Kieny MP: Prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995;11:373-381.
43. Fleury B, Janvier G, Pialoux G, Buseyne F, Robertson MN, Tartaglia J, Paoletti E, Kieny MP, Excler JL, and Rivière Y: Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV) negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-738.
44. McElrath MJ, Siliciano RF, and Weinhold KJ: HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation. AIDS Res Hum Retroviruses 1997;13:211-216.
45. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh R-H, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler J-L, Tartaglia J, Duliege A-M, Sinangil F, Paoletti E, and the NIAID AIDS Vaccine Evaluation Group: Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-1246.
46. Lubaki M, Egan MA, Siliciano RF, Weinhold KJ, and Bollinger RC: A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. AIDS Res Hum Retroviruses 1994;10:1423-1427.
47. Sipas NV, Kalams SA, Trocha A, He S, Blattner WA, Walker BD, and Walker RP: Identification of type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory workers accidentally infected with HIV-1. J Clin Invest 1997;99: 752-762.
48. Dal Porto J, Johnson TE, Catipovi B, Parfiit DJ, Tuveson D, Gether U, Kozlowskoki S, Fearon DT, and Schneck JP: A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci USA 1993;90:6671-6675.
49. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J, McMichael A, and Gotch F: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med 1995;1:1167.
50. Lubaki NM, Ray SC, Dhruva B, Quinn TC, Siliciano RF, and Bollinger RC: Characterization of a polyclonal cytolytic T lymphocyte response to human immunodeficiency virus in persons without clinical progression. J Infect Dis 1997;175:1360-1367.
51. Watanabe H, Matsyshita S, Kamikawaji N, Hirayama K, Okumura M, and Sasazuki T: Immune suppression on HLA-Bw54-DR4-DRw53 haplotype nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol 1988;22:9-17.
52. Kruskall MS, Alper CA, Awdeh Z, Ennis EJ, and Marcus-Bagley D: The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 1992;175:495-502.
53. Ogata M, Ishikawa H, Kato Y, Honta S, Yoshida H, Yasuda H, Ohio H, and Watanabe N: Antibody responses in human beings to pre-S2 and related hepatitis B virus-envelope antigens in vivo and in vitro. Rinsho Byori 1991;39:3-13.
54. Weissman JY, Tsuchiyose MM, Tong MJ, Co R, Chin K, and Ettenger RB: Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA 1988;260:1734-1738.
55. Palumbo P, Hoyt L, Demasio K, Oleske J, and Connor E: Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992;11:1008-1014.
56. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJ, Simmonds P, Morrison H, and Jones M: HLA haplotype A1, B8, DR3 as a risk factor for HIV-related disease. Lancet 1998;1:1185-1188.
57. Just JJ, Abrams E, Louie LG, Urbano R, Wara D, Nicholas SW, Stein Z, and King MC: Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1. J Pediatr 1995;127: 544-549.
58. Louie LG, Newman B, and King MC: Influence of host genotype on progression to AIDS among HIV-infected men. J Acquir Immun Defic Syndr 1991;4:814-818.
59. Lieberman J, Fabry JA, Fong DM, and Parkerson GR: Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses 1997;13:383-388.
60. Walker BD and Koup R: HIV-1 CTL epitopes. In: HIV Molecular Database (Korber BTM, Moore JP, Brander C, Koup R, Haynes BF, and Walker BD, eds.). Theoretical Biology and Biophysical Group, Los Alamos, New Mexico, 1997.
61. Ferrari G, Humphrey W, McElrath MJ, Excler JL, Duliege AM, Clements ML, Corey LC, Bolognesi DP, and Weinhold KJ: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401.
62. Cao H, Kanki P, Sankale JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, and Walker BD: Cytotoxic T lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
63. Bennett RG, Powers DC, Remsburg RE, Scheve A, and Clements ML: Hepatitis B virus vaccination for older adults. J Clin Microbiol 1996;44:699-703.
64. Desombre I, Hauser P, Rossau R, Paradijs L, and Leroux-Roels G: Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995;154:520-529.
65. Hayney MS, Poland GA, Dimanlig P, Schiad DJ, Jacobson RM, and Lipsky JJ: Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 1997; 15:3-6.
66. Monaco JJ, Cho SS, and Attaya M: Transport protein genes in the murine MHC: Possible implications for antigen processing. Science 1990;250:1723-1726.
67. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, and DeMars RA: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (London) 1990;348:744-747.
68. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, and Howard JC: MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature (London) 1990;348:738-741.
69. Pantaleo G, Koenig S, Baseler M, Lane HC, and Fauci AS: Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+ CD8+DR+CD25-T cell population. J Immunol 1990;144: 1696-1704.
70. Doherty PC, Topham DJ, and Tripp RA: Establishment and persistence of virus-specific CD4+ and CD8+ T cell memory. Immunol Rev 1996;150:23-44.
71. Gotch FM, Nixon DF, Alp N, McMichael AJ, and Borysiewicz LK: High frequency of memory and effector Gag-specific cytotoxic T lymphocytes in HIV-seropositive individuals. Int Immunol 1990;2:707-712.
72. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bells JI, McMichael AJ, and Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-96.